This Antibody was verified by Knockout to ensure that the antibody binds to the antigen stated.
FIGURE: 1 / 5
Description: This MJD2 monoclonal antibody reacts with HER-2, the product of the ErbB2 gene and a member of the human epidermal growth factor receptor (EGFR) family. HER-2 is a 185 kDa transmembrane receptor with an extracellular binding domain and an intracellular tyrosine kinase domain. Activation of HER-2 occurs following formation of homodimers or heterodimers with ligand-bound EGFR family members, HER3 or HER4. Overexpression of HER-2 results in auto-phosphorylation and increased proliferation and invasiveness and is associated with subsets of multiple cancer types such as breast, ovarian, cervical, uterine, and gastric. The use of HER-2 targeted agents has been used extensively to treat HER-2-positive breast cancer, but a recent study found that these agents can also block the proliferation of breast cancer stem cells found in HER-2-negative patients and suggests the importance of HER-2 as a target for multiple types of breast cancer. The MJD2 antibody recognizes the extracellular domain of HER-2 but at an epitope distinct from that recognized by the 4D5 (Herceptin) and SP3 monoclonal antibodies.
Applications Reported: This MJD2 antibody has been reported for use in western blotting, immunohistochemical staining of formalin-fixed paraffin embedded tissue sections, microscopy, and immunocytochemistry.
Applications Tested: This MJD2 antibody has been tested by immunhistochemistry of formalin-fixed paraffin embedded human tissue using low or high pH antigen retrieval and can be used at less than or equal to 5 µg/mL. This MJD2 antibody has been tested by immunocytochemistry of methanol-fixed and permeabilized human BT474 cells and can be used at less than or equal to 5 µg/mL. This MJD2 antibody has been tested by western blot analysis of reduced human BT474 cell lysate and can be used at less than or equal to 5 µg/mL. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.
Purity: Greater than 90%, as determined by SDS-PAGE.
Aggregation: Less than 10%, as determined by HPLC.
Filtration: 0.2 µm post-manufacturing filtered.
ErbB2 (HER2) is a receptor tyrosine kinase that is overexpressed in some breast tumors. Herceptin, used in treatment of metastatic Her2-positive cancer, is monoclonal antibody targeting this kinase.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: c-erb B2/neu protein; CD antigen CD340; CD340; erb-b2; erbb 2; ErbB2 (pTyr1139); ErbB2 (pY1139); ErbB2 phospho Y1139; her 2; herstatin; human epidermal growth factor receptor 2; metas; Metastatic lymph node gene 19 protein; MLN 19; neuro/glioblastoma derived oncogene homolog; neuroblastoma/glioblastoma derived oncogene homolog; p185erbB2; phospho ErbB2; Proto-oncogene c-ErbB-2; Proto-oncogene Neu; Receptor tyrosine-protein kinase erbB-2; Tyrosine kinase-type cell surface receptor HER2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog
Gene Aliases: CD340; ERBB2; HER-2; HER-2/neu; HER2; MLN 19; MLN19; NEU; NGL; TKR1
UniProt ID: (Human) P04626
Entrez Gene ID: (Human) 2064
Molecular Function: transmembrane signal receptor